Chromosome 17 Copy Number Changes in Male Breast Cancer

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2015 Apr 24

PMID 25906114

Citations 7

Authors

Miangela M Lacle

Cathy B Moelans

Robert Kornegoor

Carmen van der Pol

Arjen J Witkamp

Elsken van der Wall

Josef Rueschoff

Horst Buerger

Paul J van Diest

Affiliations

Soon will be listed here.

Abstract

Background: Overall, HER2-amplified female breast cancer (FBC) is associated with a high grade, an aggressive phenotype and a poor prognosis. In male breast cancer (MBC) amplification of HER2, located on chromosome 17, occurs at a lower frequency than in FBC, where it is part of complex rearrangements. So far, only few studies have addressed the occurrence of chromosome 17 alterations in small MBC cohorts.

Methods: Multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH) were used to detect and characterize copy number changes on chromosome 17 in a cohort of 139 MBC. The results obtained were compared to those in FBC, and were correlated with clinicopathological features and patient outcome data.

Results: We observed a lower frequency of chromosome 17 copy number changes with less complex rearrangement patterns in MBC compared to FBC. Chromosome 17 changes in MBC included gains of 17q and losses of 17p. Whole chromosome 17 polyploidies were not encountered. Two recurrent chromosome 17 amplicons were detected: on 17q12 (encompassing the NEUROD2, HER2, GRB7 and IKZF3 gens) and on 17q23.1 (encompassing the MIR21 and RPS6KB1 genes). Whole arm copy number gains of 17q were associated with decreased 5 year survival rates (p = 0.010). Amplification of HER2 was associated with a high tumor grade, but did not predict patient survival. Although copy number gains of HER2 and NEUROD2 were associated with a high tumor grade, a high mitotic count and a decreased 5 year survival rate (p = 0.015), only tumor size and NEUROD2 copy number gains emerged as independent prognostic factors.

Conclusions: In MBC chromosome 17 shows less complex rearrangements and fewer copy number changes compared to FBC. Frequent gains of 17q, encompassing two distinct amplicons, and losses of 17p were observed, but no whole chromosome 17 polyploidies. Only NEUROD2 gains seem to have an independent prognostic impact. These results suggest different roles of chromosome 17 aberrations in male versus female breast carcinogenesis.

Citing Articles

A Retrospective View of the Triple-Negative Breast Cancer Microenvironment: Novel Markers, Interactions, and Mechanisms of Tumor-Associated Components Using Public Single-Cell RNA-Seq Datasets.

Kim M, Yang W, Hong D, Won H, Yoon S Cancers (Basel). 2024; 16(6).

PMID: 38539508 PMC: 10969223. DOI: 10.3390/cancers16061173.

Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.

Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L Front Oncol. 2023; 12:1092201.

PMID: 36686738 PMC: 9854133. DOI: 10.3389/fonc.2022.1092201.

Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer.

Kou F, Wu L, Ren X, Yang L Mol Ther Oncolytics. 2020; 17:562-570.

PMID: 32637574 PMC: 7321812. DOI: 10.1016/j.omto.2020.05.010.

The molecular genetic make-up of male breast cancer.

Moelans C, de Ligt J, van der Groep P, Prins P, Besselink N, Hoogstraat M Endocr Relat Cancer. 2019; 26(10):779-794.

PMID: 31340200 PMC: 6938562. DOI: 10.1530/ERC-19-0278.

The dark side of centromeres: types, causes and consequences of structural abnormalities implicating centromeric DNA.

Barra V, Fachinetti D Nat Commun. 2018; 9(1):4340.

PMID: 30337534 PMC: 6194107. DOI: 10.1038/s41467-018-06545-y.

References

Bunyan D, Eccles D, Sillibourne J, Wilkins E, Thomas N, Shea-Simonds J . Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer. 2004; 91(6):1155-9. PMC: 2747696. DOI: 10.1038/sj.bjc.6602121. View

Muir D, Kanthan R, Kanthan S . Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003; 127(1):36-41. DOI: 10.5858/2003-127-36-MVFB. View

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

van Diest P, Baak J, van Galen C, Kurver P, BELLOT S, Fijnheer J . Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol. 1992; 23(6):603-7. DOI: 10.1016/0046-8177(92)90313-r. View

Zhu Y, Qi C, Jain S, Le Beau M, Espinosa 3rd R, Atkins G . Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci U S A. 1999; 96(19):10848-53. PMC: 17971. DOI: 10.1073/pnas.96.19.10848. View

Conaway R, Sato S, Tomomori-Sato C, Yao T, Conaway J . The mammalian Mediator complex and its role in transcriptional regulation. Trends Biochem Sci. 2005; 30(5):250-5. DOI: 10.1016/j.tibs.2005.03.002. View

Rudlowski C, Schulten H, Golas M, Sander B, Barwing R, Palandt J . Comparative genomic hybridization analysis on male breast cancer. Int J Cancer. 2005; 118(10):2455-60. DOI: 10.1002/ijc.21646. View

Fonseca R, Tomas A, Andre S, Soares J . Evaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancer. Am J Surg Pathol. 2006; 30(10):1292-8. DOI: 10.1097/01.pas.0000213354.72638.bd. View

Hudis C . Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1):39-51. DOI: 10.1056/NEJMra043186. View

10.

Moelans C, de Weger R, Ezendam C, van Diest P . HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection. BMC Cancer. 2009; 9:4. PMC: 2631004. DOI: 10.1186/1471-2407-9-4. View

11.

Marchio C, Lambros M, Gugliotta P, Verdun di Cantogno L, Botta C, Pasini B . Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009; 219(1):16-24. DOI: 10.1002/path.2574. View

12.

Yeh I, Martin M, Robetorye R, Bolla A, McCaskill C, Shah R . Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009; 22(9):1169-75. DOI: 10.1038/modpathol.2009.78. View

13.

Moelans C, de Weger R, van Diest P . Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2009; 120(1):1-7. DOI: 10.1007/s10549-009-0539-2. View

14.

Moelans C, de Weger R, Monsuur H, Vijzelaar R, van Diest P . Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol. 2010; 23(7):1029-39. DOI: 10.1038/modpathol.2010.84. View

15.

Lambros M, Natrajan R, Geyer F, Lopez-Garcia M, Dedes K, Savage K . PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 2010; 23(10):1334-45. DOI: 10.1038/modpathol.2010.121. View

16.

Tommasi S, Mangia A, Iannelli G, Chiarappa P, Rossi E, Ottini L . Gene copy number variation in male breast cancer by aCGH. Anal Cell Pathol (Amst). 2010; 33(3):113-9. PMC: 4605520. DOI: 10.3233/ACP-CLO-2010-0544. View

17.

Hungermann D, Schmidt H, Natrajan R, Tidow N, Poos K, Reis-Filho J . Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J Pathol. 2011; 224(4):517-28. DOI: 10.1002/path.2938. View

18.

Moelans C, Reis-Filho J, van Diest P . Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncol. 2011; 12(12):1087-9. DOI: 10.1016/S1470-2045(11)70234-0. View

19.

Kornegoor R, Verschuur-Maes A, Buerger H, Hogenes M, de Bruin P, Oudejans J . Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2011; 25(3):398-404. DOI: 10.1038/modpathol.2011.174. View

20.

Hasegawa N, Sumitomo A, Fujita A, Aritome N, Mizuta S, Matsui K . Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells. Mol Cell Biol. 2012; 32(8):1483-95. PMC: 3318591. DOI: 10.1128/MCB.05245-11. View